Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
12,188 total articles
Verizon is hitting on multiple operational cylinders: accelerating fiber adds after the Frontier deal, improving postpaid phone net additions, and margin expansion that pushed free cash flow sharply higher. The stock trades at attractive multiples with a 6%+ yield; I recommend a buy for a 180-trading-day trade targeting a re-rating as execution con…
Nutex Health (NUTX) has recovered sharply from the spring lows and now trades near $202. Recent management guidance and better-than-expected margin trends argue for re-rating the stock. We upgrade to long with a $260 target and a $180 stop, looking out to a 180-trading-day horizon.
Dime Commercial Bancshares (DCOM) has moved up from its 2025 lows and now trades near $40 with a market cap of roughly $1.76B. Recent corporate actions - an announced $40M subordinated debt redemption, a reauthorized 1.57M share repurchase, a rebrand and continued quarterly dividends - pair with a dominant Long Island deposit footprint and solid ca…
After selling its Connectivity and Cable Solutions division and retiring debt, Vistance appears to be a net-cash-rich company trading below the cash-adjusted value of the business. Technicals show oversold conditions and growing bullish MACD momentum, setting up a defined-risk long trade aimed at a re-rating if management executes distributions, bu…
Pagaya Technologies is an AI-first fintech that has converted strong ABS distribution and improving operating leverage into free cash flow and earnings. The shares are trading below levels from a summer run but remain attractively valued at roughly $1.56B market cap and EV/EBITDA ~6.8. For a satellite position we recommend a disciplined long: entry…
We upgrade Societe Generale (SCGLY) to a Buy. The bank trades at a cheap P/E of 9.3 and P/B of 0.88 with a market cap of about $61.5B. Management has restarted capital returns (completed a €1bn cancellation and proposed up to 10% buyback authorization) and the balance sheet can support modest risk-taking while lifting return on tangible equity over…
DraftKings is trading near its 52-week low while fundamentals point to an asymmetric setup: strong prediction-market adoption, seasonal betting tailwinds and meaningful free cash flow versus a valuation that already discounts tough near-term optics. This trade idea lays out a clear entry, stop and $30 target and explains why H2'26 catalysts could f…
NN, Inc. (NNBR) is trading near $3.86 after a high-volume move and constructive technicals. The company has added meaningful medical business (pipeline up to $75M) and showed improving profitability despite prior revenue pressure. With market cap roughly $318.8M, a thin float and a technical breakout, we upgrade to a tactical long for a mid-term tr…
Draganfly has disappointed on execution recently, but its drone hardware and autonomous solutions remain differentiated in inspection, public safety and data services. This trade targets a bounce from oversold levels while acknowledging high execution risk. Entry $0.50, stop $0.35, target $1.25 — mid-term swing (45 trading days).
QuinStreet (QNST) has moved quickly from an insurance-heavy revenue mix toward a broader set of performance marketplaces and direct-response channels. Recent results and guidance show durable demand in financial and home services, free cash flow is healthy, and valuation metrics are modest. This idea lays out an actionable long with entry, stop and…
Microsoft's stock has recovered sharply from its June low and is now carving out the first sustainable leg higher. The business fundamentals - high free cash flow, strong ROE, and diversified cloud and productivity franchises - support continued upside. This trade idea lays out an entry at $500.78, a stop at $485.00, and a mid-term target of $540.0…
Citigroup (C) looks like a pragmatic long trade: the shares trade at a modest P/E of 14.3 and a P/B of 1.15, pay a $0.67 quarterly dividend (~1.9% yield), and are nearing an earnings cadence and rate environment that should support net interest income. We lay out an actionable long trade with entry, stop, and target and explain the key operational …
NewLake Capital Partners (NLCP) yields ~11.4% today on a quarterly $0.43 dividend that management has repeatedly covered with portfolio earnings and healthy liquidity. For income-oriented traders willing to accept sector-specific tenant risk, NLCP offers an attractive carry trade with a clear risk-reward: entry at $15.06, stop at $13.50, target $18…
Intel is back in the AI conversation. Recent product wins (Core Ultra in new Googlebook devices), improving DCAI demand and visible cash flow give the stock real upside as investors re-rate exposure to CPUs, integrated NPUs and foundry services. We reiterate Buy with a clear trade plan: enter at current levels, stop at $105, target $155 over ~180 t…
CPI Card Group (PMTS) looks like a classic buy-the-dip setup after recent share pressure from a shareholder sale and margin noise. The company generates solid revenue growth, improving free cash flow and a manageable refinancing profile; valuation is attractive versus its own history and implied enterprise value. We recommend a mid-term buy with an…
Medtronic offers a mix of reliable income (3.1% yield), above-market top-line momentum and a valuation that still leaves upside if execution on robotics and cardiac growth continues. This trade targets a measured long-term move over 180 trading days with explicit entry, stop and target levels.
MBX Biosciences has delivered a steady parade of positive clinical data across canvuparatide and early obesity candidates while setting up Phase 3 execution in Q3 2026. Recent weakness is a buying window: valuation and a concentrated short-interest backdrop amplify upside into near-term catalysts. This trade plans a long entry at $58.00 with a $48.…
Hess Midstream (HESM) offers a near‑8% yield, solid free cash flow and reasonable valuation metrics (P/E ~13.5, EV/EBITDA ~7.1). Higher oil prices and incremental Bakken production from Chevron support distribution coverage and buyback optionality. This trade targets a rebound toward $44 over the next 180 trading days with a protective stop at $34.
Tourmaline is a high-quality Canadian gas-weighted E&P with a resilient cash-flow profile. This trade idea advocates a tactical long to support the share price into seasonally stronger gas demand and near-term company catalysts. Entry, stop and target laid out with a mid-term horizon and explicit risk controls.
Crescent Capital BDC is trading around $9.67, roughly half its reported NAV. Management trimmed fees in April and declared regular and special dividends; rising interest rates and reactivated coverage could drive earnings and narrow the discount. We lay out an actionable long trade with entry, stop and target and a balanced risk framework.
Labcorp (LH) sold off after CMS proposed a 15% reimbursement cut. With CMS representing ~8% of revenue, the headline impact is contained. Margins and end-market growth (oncology, biomarkers, CRO services) underpin a recovery. This trade targets a bounce to $345 over a 180-trading-day horizon with a tight $295 stop.
Optical Cable Corp. posted better-than-expected top-line growth and margin expansion in recent quarters and a rising backlog that points to sustained revenue visibility. With a sub-$130m market cap, improving operating leverage and a partner stake from Lytera, OCC looks like a reasonable long with a clear risk-reward if management sustains revenue …
Western Midstream (WES) is trading below key moving averages after a modest pullback; the unit offers roughly an 8% yield, a $19B market cap and a sub-15x PE. For income-oriented traders willing to accept midstream cyclicality, this dip presents a disciplined long trade with defined risk and a clear 180-day target.
United Therapeutics (UTHR) is trading off recent highs but sits squarely in front of multiple regulatory catalysts — an FDA decision window for ralinepag and a late-April 2027 decision for nebulized Tyvaso in IPF. The balance sheet, free cash flow of $1.093B, and attractive profitability metrics provide a foundation for upside should approvals come…
QuinStreet delivered a materially stronger print in Q4 2026 and guided to a $1.45-$1.55B revenue range for fiscal 2027. At roughly $14.50 and a market cap near $827M, the stock trades at single-digit EV/sales and a low-teens EV/EBITDA on recent free cash flow performance. The setup is a classic growth + value mismatch: fundamental momentum plus an …
